PYC Therapeutics Limited ((AU:PYC)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PYC Therapeutics Limited is conducting a clinical study titled ‘A Phase 1b Open-Label, Randomized, Single Dose and Repeat Dose Study to Evaluate the Single and Repeat Dose Safety and Tolerability of Intravitreally Administered PYC-001 in Participants With Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy.’ The study aims to assess the safety and determine the optimal dosing regimen of PYC-001 in individuals with this genetic condition, which affects vision.
The intervention being tested is PYC-001, a peptide-phosphorodiamidate morpholino oligonucleotide, administered via eye injections. This treatment is designed to address the genetic mutation causing Autosomal Dominant Optic Atrophy (ADOA).
The study follows an interventional design with randomized allocation and a sequential intervention model. There is no masking involved, and the primary purpose is treatment-focused. Participants receive varying doses of PYC-001 to evaluate safety and efficacy.
The study began on April 28, 2025, with the latest update submitted on September 17, 2025. These dates are crucial as they mark the progress and current status of the study, which is still recruiting participants.
This update could positively impact PYC Therapeutics’ stock performance by boosting investor confidence in the company’s innovative treatments. The study’s progress may also influence the competitive landscape in the genetic eye disorder treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.